Core Viewpoint - Longshen Rongfa has recently obtained a medical device registration certificate for its blood dialysis powder, which is expected to enhance the company's product structure and create new profit growth points, positively impacting its future development [1][2]. Group 1: Product Development - The blood dialysis powder is designed for the treatment of acute and chronic renal failure and has been widely used in clinical settings [1]. - The product's registration certificate is valid from November 5, 2025, to November 4, 2030, indicating a long-term approval for market entry [1]. - The registered product has a specific ion concentration model of "Potassium 2.0, Calcium 1.5" and is available in various packaging sizes, including single-use, five-use, and ten-use formats, compatible with most dialysis machines [1]. Group 2: Market Position and Impact - Longshen Rongfa is the first company in the northwest provinces of Gansu, Qinghai, Ningxia, and Xinjiang to successfully obtain this product registration certificate, marking its entry into the medical device sector [2]. - The approval is expected to contribute to the development of the medical device industry in the northwest region of China [2].
陇神戎发：血液透析干粉获医疗器械注册证 产业布局再升级